US OptionsDetailed Quotes
COIN241213P345000
- 34.99
- +2.31+7.07%
15min DelayClose Dec 13 16:00 ET
38.26High29.35Low
31.95Open32.68Pre Close153 Volume500 Open Interest345.00Strike Price565.30KTurnover3976.76%IV0.18%PremiumDec 13, 2024Expiry Date34.42Intrinsic Value100Multiplier0DDays to Expiry0.57Extrinsic Value100Contract SizeAmericanOptions Type-0.9444Delta0.0056Gamma9.09Leverage Ratio-1112.3853Theta0.0000Rho-8.58Eff Leverage0.0006Vega
Coinbase Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
1
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
$Coinbase (COIN.US)$
BiT Global slams Coinbase with $1 billion lawsuit over delisting of WBTC
BiT Global slams Coinbase with $1 billion lawsuit over delisting of WBTC
after being a bull for $Coinbase (COIN.US)$ since my first buy at 75 dollars. i am leaning bearish with the recent complaints that users are getting locked out of their accounts.
1
$Coinbase (COIN.US)$ unbelievable moves , this is insanely! there won't be a bounce back at some point
1
3
+3
4
$Coinbase (COIN.US)$ wouldn't risk my business holding this over the weekend
2
10
$Coinbase (COIN.US)$ told u
1
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.